7. Treatment comparison to control: serious adverse events ‐ network meta‐analysis MTC.

OR RE Model	Standard Dose Model Median (95% CI)
Abatacept	0.89 (0.61 to 1.26)
Adalimumab	0.96 (0.74 to 1.27)
Anakinra	1.04 (0.67 to 1.64)
Certolizumab	1.57 (1.06 to 2.32)*
Etanercept	1.24 (0.93 to 1.69)
Golimumab	1.05 (0.67 to 1.69)
Infliximab	1.15 (0.85 to 1.57)
Rituximab	1.71 (0.69 to 4.49)
Tocilizumab	0.77 (0.41 to 1.45)
Overall	1.09 (0.97, 1.24)
Data points Residual deviance DIC	(133) 153.8 758.95

* = statistically significant; OR = odds ratio; RE model = random‐effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria